HC Wainwright & Co. Reiterates Buy on Calliditas Therapeutics, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating on Calliditas Therapeutics (NASDAQ:CALT) and maintained a $50 price target on the company's stock.
November 27, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating on Calliditas Therapeutics with a maintained price target of $50.
The reiteration of a Buy rating and the maintenance of a $50 price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on Calliditas Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100